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Summary:   
Using immunohistochemistry and flow cytometry to define phases of the cell cycle this study shows 
that, a high proportion of AML blasts obtained from trephine biopsies are cycling whereas, >95% of 
peripheral blood-derived blasts are arrested in G1. Furthermore, results obtained from bone marrow 
aspirates are more similar to those from blood rather than from the trephine biopsies, and these 
differences were confirmed by gene expression profiling in a patient with high count AML.  This has 
implications for cell cycle and other biological studies using aspirates rather than trephine biopsies 
and for the use of cell mobilizing agents before chemotherapy. 
  
In acute myeloid leukaemia (AML), leukaemic blast cells from bone marrow (BM) and peripheral 
blood (PB) are generally assumed to be biologically similar, but previous studies of cell proliferation 
have suggested differences (Hiddemann et al, 1982a; Vidriales et al, 1995). It is not clear whether 
these relate to intrinsic differences in the blast cell populations or a higher proportion of non-leukemic 
quiescent cells in PB. Most studies of BM use aspirates (BMA), although it has long been recognized 
that they can be variably ‘contaminated’ by blood cells (Holdrinet et al, 1980; Hiddemann et al, 1982b). 
Furthermore, earlier studies of the cell cycle were limited by the need for in vitro culture to measure 
3H-thymidine uptake by the proliferating cells, which was potentially subject to the influence of 
different accessory cell populations in PB and BM (Raza et al, 1990). With the availability of 
monoclonal antibodies against antigens present at different phases of the cell cycle, it is now possible, 
however, to determine the proliferative status of cells directly ex-vivo without in vitro culture 
(Williams and Stoeber, 2007).  We have therefore used immunohistochemistry to determine the cell 
cycle status of AML blasts in BM using trephine biopsies (BMT), which are not subject to blood 
contamination, and compared this finding to the findings in BMAs and PB.  
 
Methods 
 
Full experimental details are provided in the Supplementary material. The UCL/UCLH Research Ethics 
Committee approved the studies. Informed consent was obtained according to the Declaration of 
Helsinki. 
 
Analysis of cell cycle status of blast cells  
 
For immunohistochemistry, serial sections from paraffin-embedded BMT and buffy-coat cell pellets 
from BMA and PB samples were immuno-stained with monoclonal antibodies to Mcm2 to assess non-
quiescent cells (positive in G1, S, G2 and M but not G0), MIB-1 (Ki-67) for actively proliferating cells 
(positive in G1, S, G2 and M but not G0), and Geminin for cycling cells that have progressed beyond G1 
(positive in S/G2/M but not G1 and G0)(Williams and Stoeber, 2007). For each section a minimum of 
200 blasts were assessed and labeling indexes (LI) determined from the number of positive nuclear-
stained cells as a percentage of the total number of cells. For flow cytometry, the percentage of blasts 
in S/G2/M phases of the cell cycle was assessed using propidium iodide staining of fixed cells.  
 
Determination of peripheral blood-derived cells in bone marrow aspirates from haematologically normal 
individuals 
 
BMT, BMA and PB samples were collected from 13 individuals with a morphologically normal BM 
undergoing a BM harvest. The BMA samples (5-10mLs) were collected and paired with 10mLs of blood. 
Core biopsies were obtained from the posterior iliac crest and the length of the biopsy determined 
using a vernier caliper. The biopsies were then teased apart, single cell suspensions prepared, and the 
number of cells counted. Actual volumes of the collected BMT biopsies were calculated from their 
measured length and the internal cross sectional diameter of the Jamshidi needles used (4.486mm2).  
Cytospins were prepared from the BMT, BMA and PB samples, stained with May-Grunwald-Giemsa, 
and manual differential counts performed.  The volumetric contributions of BMT and PB to the BMA 
was then calculated as described with an example in the legend to Table 1. 
 
RNA expression profiling  
 
An mRNA-focused library was prepared using total RNA from BMT, BMA and PB samples processed 
within 30 minutes of collection from a patient with high count AML and then sequenced 
(Supplementary material). De-multiplexed FastQ data was processed and normalized counts (FPKM) 
were generated and visualized in GeneSpring 13.0 (Agilent Technologies). 
 
Results 
 
Cell cycle analysis of blast cells in peripheral blood, bone marrow aspirates, and bone marrow 
biopsies  
 
Matched BMT, BMA and PB samples were obtained from eight AML patients prior to therapy. Median 
age was 64 years (range, 34-74); median peripheral white cell count (WCC) was 27.5x109/L (range, 2-
365). There was no significant difference between BMT and PB samples in the proportion of blasts 
expressing Mcm2 (P=.17) (Figure 1A, Figure S1A), indicating that nearly all the blast cells were non-
quiescent, irrespective of location. The percentage of blasts in-cycle was also highly correlated 
between BMT and PB (r=.98). There was, however, a significant difference in the proportion of blasts 
expressing MIB-1, median LI 63% for BMT versus 4% for PB (P=.008) (Figure 1A, Figure S1B), 
indicating that the BMT blasts had a very high proliferative fraction whereas, in general, PB blasts 
were not actively proliferating. In accord with this, the median Geminin LI indicating progression 
beyond G1 was 24% for BMT versus 1% for PB (P=.008) (Figure 1A, Figure S1C). The MIB-1 and 
Geminin LIs for BMAs were more akin to those of PB rather than BMT blasts, suggesting that large 
volume BMAs may be heavily contaminated with blood cells.  Data from flow cytometric cell-cycle 
analysis showed good correlation between the proportion of geminin-positive and propidium iodide-
stained cells in S/G2/M, irrespective of location (r=.986) (Figure S2, Figure S3). 
 
Determination of peripheral blood derived cells in bone marrow aspirates 
 
To further assess the impact of blood contamination on BMAs, matched BMT, BMA and PB samples 
from 13 haematologically normal individuals were studied. In the BMTs, nucleated red cells comprised 
a median 28% of total nucleated cells (range, 11%-59%) compared to 0% in PB and 17% (range, 5%-
25%) in BMAs (Table 1). Overall, therefore, a median 53% of the BMA cells were BM-derived and 47% 
PB-derived. The volumetric contribution of BM and PB in the BMAs required to achieve these 
proportions is dependent on the cell concentrations. The median BMT nucleated cell count was 
91.6x109/L, which is ≈16 fold higher than the median WCC of 5.9x109/L in normal individuals 
(Simmons et al, 1974). Using this ratio and the median cellular proportions described above, it can be 
estimated that, by volume, 93% of a BMA is from PB (Table 1). If the same volumetric contribution of 
PB to a BMA also pertains to leukemic samples, it can be speculated that  a BMT count of 250x109/L 
(≈2.5x normal BM cellularity) and PB WCC of 10x109/L, 35% of the BMA nucleated cells will be PB-
derived cells, but if the PB WCC is 100x109/L, this proportion rises to 84%.  
 
Comparison of peripheral blood, bone marrow aspirate, and bone marrow biopsy by gene expression 
profiling 
 
Gene expression profiling of BMT, BMA and PB samples was carried out from a patient with a 
presenting WCC of 98x109/L and >90% blasts in all three samples, precluding any need for blast cell 
purification. Evaluable data was obtained from 10,363 genes. There were 472 non-stromal genes 
expressed at ≥2 fold higher levels in the BMT than PB, of which 146 were related to the cell-cycle, 
including members of the Mcm family, Geminin, and MKI67 encoding Ki-67 (Table S2). The cell-cycle 
expression profile of the BMA was clearly more akin to that of PB than BMT (Figure 1B). 
 
 
 
Discussion 
 
These data demonstrate that the majority of blasts in peripheral blood exist in a G1 arrested state and 
are not actively proliferating.  This is in marked contrast to blast cells obtained from biopsies where 
although a similar number of blasts are in-cycle as defined by Mcm2 expression, a far greater number 
are actively proliferating and have progressed beyond G1 into S/G2/M. Furthermore, we demonstrate 
that BMAs are heavily contaminated with PB derived blasts when the PB cell count is high and if cell 
proliferation studies are performed on BMA, paradoxically, the cell proliferation rates would appear 
lower in those cases with the highest peripheral counts. This might account for some of the reported 
inconsistencies on the impact of cell-cycle status on outcome in AML (Hiddemann et al, 1982a; Preisler 
et al, 1984; Raza et al, 1990; Raza et al, 1991; Vidriales et al, 1995; Braess et al, 2001). The differences 
may be less pronounced if small volume aspirates are taken, but this is often not the case when cells 
are required for immune-phenotyping, cytogenetics, molecular analyses and bio-banking.  This 
indicates that studies of cell cycle analysis in AML must use BMTs and not be based on the findings in 
BMAs. 
 
These findings are supported by the gene expression profiling of matched BMT, PB, and BMA samples 
from a patient with AML, where the gene expression of BMT blasts is shown to be distinct from BMA 
blasts which are very similar to PB blasts. A large proportion of the discrepancies between BMT and 
BMA/PB samples were genes with a role in the cell cycle but other genes were also differentially 
expressed including the down-regulation of 17 transcription factors in the BMA/PB samples.  This 
suggests another level of complexity in the interpretation of BMA gene expression profiling to 
ascertain prognosis in AML and to understand the biology of normal haematopoiesis. 
 
 
Finally, these studies suggest that circulating blasts will be less susceptible to treatment with cell-cycle 
phase specific agents such as cytosine arabinoside, the mainstay of current AML therapy. Nevertheless, 
by virtue of not having entered quiescence, these cells may be capable of rapid proliferation if they 
recirculate back to the BM.   This is particularly relevant to the potential use of CXCR4 inhibitors to 
mobilize blast cells into the circulation prior to the administration of chemotherapy (Nervi et al, 2009).  
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Figure legend 
 
Figure 1. Comparison of blast cells from matched bone marrow trephine, bone marrow aspirate 
and peripheral blood samples from AML patients. (A) Relative proportion of blasts that were 
licenced for replication as defined by Mcm2 staining, were actively cycling as defined by MIB-1 
staining, and had progressed beyond G1 into S/G2/M phase as defined by Geminin staining.  (B) Heat 
map showing RNA expression analysis of 149 cell cycle-related genes with >2 fold difference in 
expression between BMT and PB samples from an AML patient. Of these, 146 were down-regulated 
and 3 were up-regulated in PB compared to the BMT. The colour range refers to the median 
normalized loge2 values across samples. LI, labelling index (number of positive cells as a percentage of 
total number of positive and negative cells); IHC, immunohistochemistry. 
 
 
 
  
Table 1. Derivation of the proportion of BM- and PB-derived cells in bone marrow aspirate 
samples from 13 hematologically normal individuals and calculation of the median volumetric 
contribution of PB in the aspirates.  
 
 
No. BMT PB BMA 
 Nucleated 
cell count 
(x 109/L) 
% nucleated 
red cells 
% nucleated 
red cells 
% nucleated 
red cells 
Proportion of BM-
derived cells* 
Proportion of 
PB-derived cells* 
1 118.0 12% 0% 5% 42% 58% 
2 84.4 20% 0% 20.5% 100% 0% 
3 165.0 45% 0% 24% 53% 47% 
4 91.6 23% 0% 10% 43% 57% 
5 187.0 59% 0% 11% 19% 81% 
6 55.0 24% 0% 23% 96% 4% 
7 68.0 32% 0% 15% 47% 53% 
8 374.0 36% 0% 25% 69% 31% 
9 130.5 33% 0% 16.5% 50% 50% 
10 79.1 19% 0% 15.5% 82% 18% 
11 85.0 28% 0% 20% 71% 29% 
12 88.9 31% 0% 16.5% 53% 47% 
13 158.0 11% 0% 17% 100% 0% 
Median 
(range) 
91.6 
(55-374) 
28% 
(11-59%) 
0% 17% 
(5-25%) 
53% 
(19-100%) 
47% 
(0-81%) 
 
*The proportion of BMT- and PB-derived cells in the BMA samples has been calculated from the % 
nucleated red cells in the BMT, PB and BMA samples from each individual. As the % of nucleated red 
cells in the blood is in all cases zero, the % nucleated red blood cells in the BMA is the % nucleated red 
blood cells in the BMT x the fraction of the BMA composed of the BMT by volume.  For example, for 
individual 1, the BMA had 5% nucleated red cells, which is 12%(% nucleated red cells in the trephine), 
multiplied by x where x is the fraction of BMA contributed by the BMT. Therefore x =5/12 = 0.42 = 
42% and therefore 58% of the cells must have come from the PB. 
  
Abbreviations: BM, bone marrow; BMA, bone marrow aspirate; BMT, bone marrow trephine; PB, 
peripheral blood. 
 
 
 
